Prader-Willi Syndrome
poster:
The Novel MetAP2 inhibitor, ZGN-1258, Reduces Body Weight and Food Intake in Mouse Models of Obesity Foundation for Prader-Willi Research 2018 Symposium & Family Conference, October 2018
poster:
ZGN-1258: A Novel Potent MetAP2 Inhibitor With Reduced Risk of Coagulopathy Foundation for Prader-Willi Research 2018 Symposium & Family Conference, October 2018
poster:
The Novel MetAP2 inhibitor, ZGN-1258, Increases Locomotor Activity and Reduces Anxiety-Like Behavior in Mouse Models of Obesity and Anxiety Disorders Foundation for Prader-Willi Research 2018 Symposium & Family Conference, October 2018
poster:
A Non-Interventional, Observational, Natural History Study of Serious Medical Events in Prader-Willi Syndrome Foundation for Prader-Willi Research 2018 Symposium & Family Conference, October 2018
publication:
Effects of MetAP2 inhibition on hyperphagia and body weight in Prader-Willi syndrome: A randomized, double-blind, placebo-controlled trial Diabetes, Obesity and Metabolism, May 2017
publication:
The High Direct Medical Costs of Prader-Willi Syndrome Journal of Pediatrics, August 2016
poster:
poster:
Weight Loss and Improvement in Body Composition: Results from bestPWS, a Phase 3, Randomized, Placebo-Controlled, Clinical Trial of Beloranib in Patients with Prader Willi Syndrome Endocrine Society, April 2016, Poster LBSun-41
poster:
Randomized, Double-Blind, Placebo-Controlled, 4 Week Proof of Concept Trial of Beloranib, a Novel Treatment for Patients With Prader-Willi Syndrome European Congress on Obesity, May 2015, Poster # 111
